CU24039B1 - Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 - Google Patents

Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17

Info

Publication number
CU24039B1
CU24039B1 CU2011000235A CU20110235A CU24039B1 CU 24039 B1 CU24039 B1 CU 24039B1 CU 2011000235 A CU2011000235 A CU 2011000235A CU 20110235 A CU20110235 A CU 20110235A CU 24039 B1 CU24039 B1 CU 24039B1
Authority
CU
Cuba
Prior art keywords
imidazolidin
ona
derivatives
disposed
cyp17 inhibitors
Prior art date
Application number
CU2011000235A
Other languages
English (en)
Other versions
CU20110235A7 (es
Inventor
Mark G Bock
Christoph Gaul
Venkateshwar Rao Gummadi
Saumitra Sengupta
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42357251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24039(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20110235A7 publication Critical patent/CU20110235A7/es
Publication of CU24039B1 publication Critical patent/CU24039B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona los compuestos de la fórmula (I), y (II), o una sal farmacéuticamente aceptables de los mismos: ESPACIO PARA LAS FÓRMULAS en donde R50, R51, R52, R53, R54, p, q, r y n son como se definen en la presente, los cuales son útiles como inhibidores de 17alfa-hidroxilasa/liasa-C17,20.
CU2011000235A 2009-06-26 2011-12-19 Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 CU24039B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1500CH2009 2009-06-26
IN2181DE2009 2009-10-21
PCT/EP2010/059029 WO2010149755A1 (en) 2009-06-26 2010-06-24 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17

Publications (2)

Publication Number Publication Date
CU20110235A7 CU20110235A7 (es) 2012-06-21
CU24039B1 true CU24039B1 (es) 2014-11-27

Family

ID=42357251

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000235A CU24039B1 (es) 2009-06-26 2011-12-19 Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17

Country Status (44)

Country Link
US (3) US8263635B2 (es)
EP (1) EP2445903B1 (es)
JP (1) JP5456891B2 (es)
KR (1) KR101360725B1 (es)
CN (1) CN102803250B (es)
AR (1) AR078228A1 (es)
AU (1) AU2010264698C1 (es)
BR (1) BRPI1015568B8 (es)
CA (1) CA2765983C (es)
CL (1) CL2011003266A1 (es)
CO (1) CO6480927A2 (es)
CR (1) CR20110684A (es)
CU (1) CU24039B1 (es)
CY (1) CY1115426T1 (es)
DK (1) DK2445903T3 (es)
DO (1) DOP2011000399A (es)
EA (1) EA021011B1 (es)
EC (1) ECSP12011625A (es)
ES (1) ES2475945T3 (es)
GE (1) GEP20156250B (es)
HK (1) HK1164876A1 (es)
HN (1) HN2011003371A (es)
HR (1) HRP20140593T1 (es)
IL (1) IL216741A (es)
JO (1) JO2892B1 (es)
MA (1) MA33451B1 (es)
ME (1) ME01886B (es)
MX (1) MX2011013771A (es)
MY (1) MY155570A (es)
NI (1) NI201100223A (es)
NZ (1) NZ596488A (es)
PE (1) PE20121048A1 (es)
PL (1) PL2445903T3 (es)
PT (1) PT2445903E (es)
RS (1) RS53384B (es)
SG (1) SG176105A1 (es)
SI (1) SI2445903T1 (es)
SM (1) SMT201400091B (es)
TN (1) TN2011000611A1 (es)
TW (1) TWI492942B (es)
UA (1) UA105794C2 (es)
UY (1) UY32730A (es)
WO (1) WO2010149755A1 (es)
ZA (1) ZA201108373B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2445502T5 (pl) 2009-06-25 2023-03-13 Alkermes Pharma Ireland Limited Związki heterocykliczne do leczenia zaburzeń neurologicznych i psychologicznych
KR101926320B1 (ko) 2010-08-04 2018-12-06 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
WO2012035078A1 (en) * 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
EP2663189B1 (en) 2011-01-11 2018-07-04 Novartis AG Combination of bortezomib with afuresertib and use thereof in the treatment of cancer
CA2834224A1 (en) * 2011-04-28 2012-11-01 Novartis Ag 17.alpha.-hydroxylase/c17,20-lyase inhibitors
PL3318554T3 (pl) * 2011-08-26 2022-01-17 Meiji Seika Pharma Co., Ltd. Sposób wytwarzania środka do zwalczania szkodników
US8969586B2 (en) 2011-09-27 2015-03-03 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN102702223A (zh) * 2012-05-28 2012-10-03 盛世泰科生物医药技术(苏州)有限公司 一种2-溴-4-氯噻吩并[3,2-c]吡啶的制备方法
MX2014014969A (es) 2012-06-06 2015-03-13 Novartis Ag Combinacion de un inhibidor de la 17-alfa-hidroxilasa (c17,20-liasa) y un inhibidor especifico de la pi-3k para tratar una enfermedad tumoral.
AU2014241816B9 (en) 2013-03-14 2019-02-14 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
TW201534586A (zh) * 2013-06-11 2015-09-16 Orion Corp 新穎ｃｙｐ１７抑制劑／抗雄激素劑
US9981928B2 (en) 2013-06-20 2018-05-29 Bayer Cropscience Aktiengesellschaft Aryl sulfide derivatives and aryl sulfoxide derivatives as acaricides and insecticides
CN109806266A (zh) * 2013-10-01 2019-05-28 诺华股份有限公司 用于癌症治疗的组合及其应用
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US10093620B2 (en) 2014-09-12 2018-10-09 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
US9783527B2 (en) * 2014-09-16 2017-10-10 Abbvie Inc. Indazole ureas and method of use
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
KR20170129802A (ko) 2015-03-10 2017-11-27 아두로 바이오테크, 인코포레이티드 ＂인터페론 유전자의 자극인자＂-의존적 신호전달을 활성화하는 조성물 및 방법
EP3327004B1 (en) 2015-07-17 2020-11-04 Fujifilm Corporation Nitrogen-containing heterocyclic compound
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
HRP20220436T1 (hr) 2015-11-03 2022-05-27 Janssen Biotech, Inc. Protutijela koja se specifično vežu na pd-1 i njihove uporabe
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP3464321B1 (en) * 2016-06-06 2023-01-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Proteasome inhibitors
WO2017211818A1 (en) * 2016-06-06 2017-12-14 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Proteasome inhibitors
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018080933A1 (en) 2016-10-24 2018-05-03 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
AU2017385292B2 (en) 2016-12-27 2020-05-14 Fujifilm Corporation Antitumor agent and bromodomain inhibitor
CN108264509B (zh) * 2016-12-30 2021-05-04 复旦大学 取代的苯并噻吩并[2，3-c]四氢吡啶衍生物及其制备方法和用途
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
EP3679028A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydroquinolinones
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略
KR20200135827A (ko) * 2018-03-22 2020-12-03 오리진 디스커버리 테크놀로지스 리미티드 Prmt5 억제제로서 치환된 이미다졸리딘-2-온 유도체
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
JP7526783B2 (ja) 2019-08-08 2024-08-01 ラークナ・リミテッド 癌を処置する方法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202321210A (zh) * 2021-07-22 2023-06-01 瑞士商諾華公司 用於治療冠狀病毒相關疾病之化合物及組成物
CN115304591A (zh) * 2022-07-08 2022-11-08 广州中医药大学(广州中医药研究院) 一种桥环甾体合成酶抑制剂及其制备方法和应用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL39283A (en) * 1971-05-03 1976-01-30 Ciba Geigy Ag Substituted 2-oxo or thioxo-3-(5-nitro-imidazol-2-yl)-tetrahydroimidazoles and their manufacture
CH590266A5 (es) * 1972-10-04 1977-07-29 Ciba Geigy Ag
DE2701794A1 (de) * 1976-01-21 1977-07-28 Ciba Geigy Ag Oxigenierte n-aryl-diazacyclen
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
ZA882717B (en) 1987-04-22 1988-10-17 Merrell Dow Pharmaceuticals Inc. 17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US4966898A (en) 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
AU659632B2 (en) 1991-03-01 1995-05-25 Electrostatic Technology, Inc. Powder coating method for producing circuit board laminae and the like
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5457102A (en) 1994-07-07 1995-10-10 Janssen Pharmaceutica, N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives
CA2132449C (en) 1992-03-31 2002-09-10 Susan E. Barrie 17 - substituted steroids useful in cancer treatment
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
US5270329A (en) * 1992-12-10 1993-12-14 Eli Lilly And Company Antitumor compositions and methods of treatment
DE4332168A1 (de) * 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
JP3916092B2 (ja) 1993-09-17 2007-05-16 杏林製薬株式会社 イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬
NZ273367A (en) 1993-09-30 1997-07-27 British Tech Group Preparation of 3<beta>-hydroxy (or lower acyloxy)-16,17-ene-17-(2-pyridyl)-substituted steroids using a palladium complex catalysed cross coupling reaction
HUT75871A (en) 1993-09-30 1997-05-28 Yamanouchi Co Azole derivatives and pharmaceutical compositions thereof
WO1996014090A1 (en) 1994-11-07 1996-05-17 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
JPH08176111A (ja) * 1994-12-20 1996-07-09 Kyorin Pharmaceut Co Ltd Ｎ，ｎ′−ジ置換エチレンジアミン誘導体及びそれらを用いたｎ，ｎ′−ジ置換イミダゾリジノン誘導体の製造方法
PT817775E (pt) 1995-03-30 2002-01-30 Pfizer Derivados de quinazolina
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU6015796A (en) 1995-06-14 1997-01-15 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
PT836605E (pt) 1995-07-06 2002-07-31 Novartis Ag Pirrolopirimidinas e processos para a sua preparacao
AU1592697A (en) 1995-08-22 1997-03-19 Du Pont Merck Pharmaceutical Company, The Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
PL190489B1 (pl) 1996-04-12 2005-12-30 Warner Lambert Co Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
EP0901489A1 (en) * 1996-05-20 1999-03-17 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE69734513T2 (de) 1996-06-24 2006-07-27 Pfizer Inc. Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
AU4141697A (en) 1996-09-06 1998-03-26 Obducat Ab Method for anisotropic etching of structures in conducting materials
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
PT941227E (pt) 1996-11-18 2004-08-31 Biotechnolog Forschung Mbh Gbf Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
NZ501822A (en) 1997-10-02 2001-12-21 Yukijirushi Nyugyo Kabushiki K Therapeutic agents for male and female sex hormone dependent diseases
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
MXPA00008365A (es) 1998-02-25 2002-11-07 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios y analogos de las mismas.
EP1073640B1 (en) 1998-04-23 2005-04-13 Takeda Pharmaceutical Company Limited Naphthalene derivatives, their production and use
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
DK1140173T4 (da) 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
BR0009507A (pt) 1999-03-30 2002-01-15 Novartis Ag Derivados de ftalazina para o tratamento de doenças inflamatórias
JP2004501066A (ja) 2000-01-28 2004-01-15 ブリストル−マイヤーズ　スクイブ　カンパニー 脂肪酸結合タンパク質のテトラヒドロピリミドンインヒビターおよび方法
JP2002302488A (ja) * 2000-03-30 2002-10-18 Takeda Chem Ind Ltd 置換１，３−チアゾール化合物、その製造法および用途
NO312876B1 (no) * 2000-07-21 2002-07-15 Balans Man As Regulerbar stol
WO2002020493A2 (en) 2000-09-06 2002-03-14 Chugai Seiyaku Kabushiki Kaisha A traceless solid-phase synthesis of 2-imidazolones
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US20040198773A1 (en) 2001-09-26 2004-10-07 Barry Hart Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
GB0200283D0 (en) * 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
ATE548354T1 (de) 2002-07-24 2012-03-15 Ptc Therapeutics Inc Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
ES2325687T3 (es) 2002-09-18 2009-09-14 Pfizer Products Inc. Compuestos de imidazol novedosos como inhibidores del factor de crecimiento transformante (tgf).
GB0418900D0 (en) 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
US20080070867A1 (en) * 2005-01-19 2008-03-20 Metabasis Therapeutics, Inc. 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases
SI2206719T1 (sl) 2005-03-02 2015-03-31 University Of Maryland, Baltimore Farmacevtski sestavek obsegajoäś 3-beta-hidroksi-17-(1-h-benzimidazol-1-il)androsta-5,16-dien
US20090264650A1 (en) * 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
EP2010524A2 (en) 2006-03-21 2009-01-07 Epix Delaware, Inc. S1p receptor modulating compounds
EP2063963A2 (en) 2006-08-25 2009-06-03 Cougar Biotechnology, Inc. Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent
US20110039893A1 (en) * 2006-10-11 2011-02-17 Takeda Pharmaceutical Company Limited Gsk-3beta inhibitor
WO2008094556A2 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
WO2008154382A1 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
CN101084881B (zh) 2007-06-23 2012-08-29 淮北辉克药业有限公司 靶向速释泡腾制剂及其制备方法
WO2009078992A1 (en) * 2007-12-17 2009-06-25 Amgen Inc. Linear tricyclic compounds as p38 kinase inhibitors
MX2010008375A (es) * 2008-01-30 2011-03-04 Cephalon Inc Star Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3).
CN102099340A (zh) * 2008-05-19 2011-06-15 先灵公司 作为因子ixa抑制剂的杂环化合物
JP5658664B2 (ja) 2008-06-25 2015-01-28 フォルム ファーマシューティカルズ、インコーポレイテッド １，２−二置換複素環式化合物
AU2009264242A1 (en) 2008-06-27 2009-12-30 Novartis Ag Organic compounds
WO2010045303A2 (en) 2008-10-16 2010-04-22 Schering Corporation Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
WO2010099518A2 (en) * 2009-02-27 2010-09-02 Thesis Chemistry, Llc Method for manufacture of 2-oxoimidazolidines
US8791094B2 (en) 2009-08-07 2014-07-29 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
WO2011059969A2 (en) 2009-11-13 2011-05-19 Tokai Pharmaceuticals, Inc. Mammalian metabolites of steroids
WO2011088160A2 (en) 2010-01-15 2011-07-21 Biomarin Pharmaceutical Inc. Novel cyp17 inhibitors
GB201002563D0 (en) 2010-02-15 2010-03-31 Cambridge Entpr Ltd Compounds

Also Published As

Publication number Publication date
KR101360725B1 (ko) 2014-02-07
US20100331326A1 (en) 2010-12-30
PE20121048A1 (es) 2012-08-25
ME01886B (me) 2014-12-20
EP2445903A1 (en) 2012-05-02
JO2892B1 (en) 2015-09-15
US20140228394A1 (en) 2014-08-14
EP2445903B1 (en) 2014-03-26
UA105794C2 (uk) 2014-06-25
AU2010264698A1 (en) 2011-12-08
CL2011003266A1 (es) 2012-07-06
HRP20140593T1 (hr) 2014-08-01
GEP20156250B (en) 2015-02-25
SMT201400091B (it) 2014-09-08
CR20110684A (es) 2012-02-15
CY1115426T1 (el) 2017-01-04
TN2011000611A1 (en) 2013-05-24
KR20120035195A (ko) 2012-04-13
CA2765983A1 (en) 2010-12-29
AR078228A1 (es) 2011-10-26
USRE45173E1 (en) 2014-09-30
CN102803250A (zh) 2012-11-28
US8263635B2 (en) 2012-09-11
JP5456891B2 (ja) 2014-04-02
AU2010264698B2 (en) 2012-10-18
JP2012530763A (ja) 2012-12-06
SG176105A1 (en) 2011-12-29
BRPI1015568B1 (pt) 2020-11-17
DK2445903T3 (da) 2014-06-23
RS53384B (en) 2014-10-31
SI2445903T1 (sl) 2014-07-31
NI201100223A (es) 2012-08-03
PT2445903E (pt) 2014-07-08
CN102803250B (zh) 2014-04-16
HK1164876A1 (en) 2012-09-28
NZ596488A (en) 2012-11-30
TW201103915A (en) 2011-02-01
EA201200049A1 (ru) 2012-08-30
ECSP12011625A (es) 2012-02-29
MA33451B1 (fr) 2012-07-03
ZA201108373B (en) 2012-07-25
AU2010264698C1 (en) 2013-05-16
CA2765983C (en) 2017-11-14
IL216741A (en) 2015-08-31
MX2011013771A (es) 2012-02-22
WO2010149755A1 (en) 2010-12-29
CO6480927A2 (es) 2012-07-16
CU20110235A7 (es) 2012-06-21
EA021011B1 (ru) 2015-03-31
IL216741A0 (en) 2012-02-29
TWI492942B (zh) 2015-07-21
MY155570A (en) 2015-10-30
HN2011003371A (es) 2015-08-10
UY32730A (es) 2011-01-31
ES2475945T3 (es) 2014-07-11
PL2445903T3 (pl) 2014-08-29
BRPI1015568B8 (pt) 2021-05-25
BRPI1015568A2 (pt) 2016-08-16
DOP2011000399A (es) 2012-01-15

Similar Documents

Publication Publication Date Title
CU24039B1 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
CR20140413A (es) Inhibidores de serina/treonina cinasa
CR20130023A (es) Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
UA111770C2 (uk) Інгібітори бромдомену
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
EA201170872A1 (ru) Ингибиторы протеинкиназы
UY32640A (es) Aril-pirimidinas como inhibidoras de sintasa dfe aldosterona
CY1118093T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt
UY32660A (es) Derivados aminobutricos sustituidos como inhibidores de neprilisina
EA201590284A1 (ru) Дигидропиридон р1 в качестве ингибиторов фактора xia
CR20110634A (es) Inhibidores de fosfoinositida 3 cinasa y/ u objetivo mamifero de rapamicina
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
EA201590277A1 (ru) Дигидропиридон р1 в качестве ингибиторов фактора xia
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
UY32432A (es) Compuestos de pirimidina fusionada como inhibidores de akt
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
CO6361924A2 (es) Nuevas lactamas como inhibidores de beta secretasa
ECSP11011485A (es) Espiro-epóxidos como productos intermedios.
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
UY32748A (es) 2-carboxamida-cicloamino-ureas
EA201170997A1 (ru) Производные индола в качестве противораковых агентов
CY1117011T1 (el) Παραγωγα αζολιου
EA201190031A1 (ru) Производные сульфамоил-фенил-уреидо-бензаимидина в качестве противомалярийных агентов
HN2010000739A (es) Inhibidores de quinasa c-fms

Legal Events

Date Code Title Description
FG Grant of patent